A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.

Also called NCT03723655

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 314 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03723655
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03723655. Randomized; triple masking; primary purpose treatment. Start 2018-09-27 (actual); primary completion 2026-01-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Condition
Hypertrophic Cardiomyopathy
Condition
Obstructive Hypertrophic Cardiomyopathy
Condition
Non-obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
mavacamten
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct03723655
Content hash
b35f7bb864f5c65edda16367f6721c0f7df49d7e8f0cf00b00e20be679609264